DQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DQ is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has no strong proprietary buy signal, the technical trend is still bearish, analysts are cautious with a lower price target, and there are no fresh news catalysts. While options positioning is slightly bearish and sentiment is mixed, the setup does not support an immediate long-term buy. The clearest direct call is to hold off and avoid buying now.
Current price is 19.1, slightly above the latest option price reference of 18.75 and near pivot resistance/support structure. The trend is weak: MACD histogram is negative and still contracting, RSI_6 at 38.6 is weak but not oversold, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key levels show resistance at 20.10 and 20.72, with support at 18.12 and 17.50. Overall, price action is still in a bearish trend and has not confirmed a reversal. Short-term pattern stats suggest only modest near-term upside, but the current setup is not strong enough for a confident long-term entry.
["Post-market move was positive at 1.87%, showing some short-term bounce interest.", "Short-term pattern statistics suggest a possible 2.99% move higher over the next month.", "The company may get support if minimum price floor guidance is refreshed in June, as referenced by analysts."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Roth Capital cut its price target to $19 from $25 and kept a Neutral rating.", "Analysts cited a Q1 miss, weak average selling prices, and possible $100M inventory impairment.", "Management may need to lower utilization/production and sell at market prices if guidance does not improve.", "Technical trend remains bearish with MACD below zero and bearish moving averages."]
Latest quarter season: Q1. Financials were weak, with analysts highlighting a Q1 miss, gross margin pressure from weak average selling prices, and a possible $100M inventory impairment. This points to deteriorating operating profitability and limited near-term growth visibility rather than a healthy growth trend.
Analyst sentiment is cautious. Roth Capital lowered the price target first to $25 from $30 on March 4 and then to $19 from $25 on April 29, while maintaining a Neutral rating both times. The trend in Wall Street views is clearly negative on target revisions and still sidelines the stock until there is better visibility on industry reform. Pros: there is still some confidence that policy support or a refreshed price floor could help. Cons: repeated target cuts, Q1 miss, margin weakness, and inventory concerns make the Street view defensive rather than bullish.
